Manchester, UK-based Concept Life Sciences, an integrated drug discovery, development and analytical services company, has acquired Scottish contract research organisation Aquila BioMedical.
Aquila, a University of Edinburgh spin out, has expertise in preclinical contract research on therapeutics for oncology, biomarker discovery, and target expression, with services covering a wide range of in vitro and in vivo proof-of-concept studies.
According to Concept, the acquisition is “a pivotal addition” to its own services supporting the drug discovery and development process.
“The company’s offering in translational biology adds significant value to our current discovery services, and broadens the wider group’s therapy offering,” noted Concept’s executive chairman Michael Fort.
Financial terms of the deal were not disclosed.
By Selina McKee
Source: Pharma Times
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
